Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163474 | 0.92 | HDAC4 (0.64) | HDAC4MEN1KMT2APGRRORC | |
| SCHEMBL7001864 | 0.90 | HDAC4 (0.66) | HDAC4MEN1KMT2APGRRORC | |
| SCHEMBL7201251 | 0.88 | HDAC4 (0.48) | HDAC4MEN1KMT2APGRHIF1A | |
| SCHEMBL7537746 | 0.87 | HDAC4 (0.54) | HDAC4MEN1KMT2ARORCHIF1A | |
| SCHEMBL5164306 | 0.87 | HDAC4 (0.48) | HDAC4MEN1KMT2APGRRORC | |
| SCHEMBL7614121 | 0.85 | HDAC4 (0.46) | HDAC4MEN1KMT2APGRHIF1A | |
| SCHEMBL7722661 | 0.84 | HDAC4 (0.46) | HDAC4MEN1KMT2APGRHIF1A | |
| SCHEMBL7558207 | 0.84 | HDAC4 (0.46) | HDAC4MEN1KMT2APGRHIF1A | |
| SCHEMBL7538308 | 0.82 | HDAC4 (0.54) | HDAC4MEN1KMT2ARORCHIF1A | |
| SCHEMBL14311955 | 0.81 | HDAC4 (0.71) | HDAC4MEN1KMT2APGRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224172-B1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | ACTIVE BIOTECH AB (SE) | 2007-04-04 | — | — | EP | claimed |
| EP-1095021-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2003-09-17 | — | — | EP | claimed |
| US-6395750-B1 | Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer | ACTIVE BIOTECH AB (SE) | 2002-05-28 | — | — | US | claimed |
| EP-1095021-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-05-02 | — | — | EP | claimed |
| US-6133285-A | 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS | ACTIVE BIOTECH AB (SE) | 2000-10-17 | — | — | US | claimed |
| WO-2000003991-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2000-01-27 | — | — | WO | claimed |
| US-20240122915-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | ACTIVE BIOTECH AB (SE) | 2024-04-18 | — | — | US | disclosed |
| CN-107427583-B | Combination of Taquinomod or a pharmaceutically acceptable salt thereof with a PD-1 and/or PD-L1 inhibitor for use as a medicament | 活跃生物技术有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3268031-B1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | ACTIVE BIOTECH AB (SE) | 2020-11-04 | — | — | EP | disclosed |
| US-20200129499-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | ACTIVE BIOTECH AB (SE) | 2020-04-30 | — | — | US | disclosed |
| US-20180050030-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | ACTIVE BIOTECH AB (SE) | 2018-02-22 | — | — | US | disclosed |
| EP-3268031-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016146329-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2016-09-22 | — | — | WO | disclosed |
| EP-3067062-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD1 AND/OR PDL1 INHIBITOR, FOR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2016-09-14 | — | — | EP | disclosed |
| EP-1224172-B1 | DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS | ACTIVE BIOTECH AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| EP-1095021-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| US-6593343-B2 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020173519-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| US-6395750-B1 | Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer | ACTIVE BIOTECH AB (SE) | 2002-05-28 | — | — | US | disclosed |
| US-6133285-A | 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS | ACTIVE BIOTECH AB (SE) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050030-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | PDCD1, CD274, PDCD1LG2 | HDAC4 335/4885MEN1 2039/4885KMT2A 708/4885 |
| US-20020173519-A1 | Quinoline derivatives | CASP1, NFKBIA, IL1B | HDAC4 1771/4885MEN1 1499/4885KMT2A 3692/4885 |
| US-20200129499-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | PDCD1, CD274, PDCD1LG2 | HDAC4 335/4885MEN1 2039/4885KMT2A 708/4885 |
| US-20240122915-A1 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | PDCD1, CD274, PDCD1LG2 | HDAC4 335/4885MEN1 2039/4885KMT2A 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.